ABVX's Quality Score fell 2 points on Tue, Nov 10, to -2. Trading picked back up (2 chart checks stopped).
Follow ABVX's trial news. Pro members can get an alert when Abivax SA files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 3.4% today, while its biotech peers are down 1.4%; no story names it yet.
Down
Down 31% in 3 months while the S&P 500 fell 2%.
−2Long-term trend
| Holding it back | A €336M loss |
| Latest filing | 10-Q, Mar 23 |
TodayNo story names it yet.
Expected to report Mon Mar 22, after the close
The company says its cash lasts into Q4 2029 (8-K, Sep 21).
No shelf registration or at-the-market program on file in the last three years.
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ABVX is #163 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 163 |
Expected to report Mon Mar 22, after the close (in 132 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Sep 21, 2026 | -0.7% | -5.0% | -6.4% |
RSI 49.4, MACD above signal, below both averages. Not scored.
In ETFs: ABVX is under 0.1% of VXUS, the most of the 24 funds Breakaway covers, by their holdings as filed for Jul 31, 2026.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
ABVX scores -2 today, which Breakaway calls Poor. It is #163 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 31% in 3 months while the S&P 500 fell 2%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ABVX scores -2 today, which Breakaway calls Poor (below zero). That is #163 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ABVX's -2.
Expected to report Mon Mar 22, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ABVX closed higher after 0 of its last 1 report. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.